Nordic Capital-backed LEO Pharma to acquire dersimelagon rights from Bain-owned Tanabe for $435m
LEO Pharma, which the release describes as a global leader in medical dermatology, serves close to 100 million patients in more than 70 countries annually. The post Nordic Capital-backed LEO Pharma to acquire dersimelagon rights from Bain-owned Tanabe for $435m appeared first on…
LEO Pharma, which the release describes as a global leader in medical dermatology, serves close to 100 million patients in more than 70 countries annually. The post Nordic Capital-backed LEO Pharma to acquire dersimelagon rights from Bain-owned Tanabe for $435m appeared first on…
BELLINGS Intelligence Score: 12
Why it matters
This is a routine private-equity-backed acquisition of drug rights, representing ordinary market activity with limited broader impact on credit markets or underwriting standards.
Sources
PE Hub
Nordic Capital-backed LEO Pharma to acquire dersimelagon rights from Bain-owned Tanabe for $435m
LEO Pharma, which the release describes as a global leader in medical dermatology, serves close to 100 million patients in more than 70 countries annually. The post Nordic Capital-backed LEO Pharma to acquire dersimelagon rights from Bain-owned Tanabe for $435m appeared first on…